The treatment of PD with levodopa remains the mainstay of disease management. Severe PD can also be treated with DBS.

DBS is a surgical procedure which connects an electrode implanted in the brain to a neurotransmitter located in the chest wall. Reduced consumption of levodopa is a frequently cited benefit of DBS. The aim of this analysis is to evaluate what effect the introduction of DBS in 2002 had on Australia’s levodopa equivalent dose (LED). Monthly utilisation data from Medicare Australia are analysed. Regression with fixed effects indicated that, by 2013, DBS had resulted in approximately a 10% reduction in the prescribed LED. The reduction in the daily LED per DBS recipient was estimated to be 450 mg. 

Project members

Contact and investigator

Dr David Rowell

Postdoctoral Research Fellow
Centre for the Business and Economics of Health

Investigator

Professor Luke Connelly

Acting Director
Centre for the Business and Economics of Health